277 related articles for article (PubMed ID: 19965667)
1. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Saussele S; Lauseker M; Gratwohl A; Beelen DW; Bunjes D; Schwerdtfeger R; Kolb HJ; Ho AD; Falge C; Holler E; Schlimok G; Zander AR; Arnold R; Kanz L; Dengler R; Haferlach C; Schlegelberger B; Pfirrmann M; Müller MC; Schnittger S; Leitner A; Pletsch N; Hochhaus A; Hasford J; Hehlmann R;
Blood; 2010 Mar; 115(10):1880-5. PubMed ID: 19965667
[TBL] [Abstract][Full Text] [Related]
2. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Luo Y; Zhao Y; Tan Y; Shi J; Han X; Zheng Y; Li L; He J; Xie W; Ye X; Cai Z; Lin M; Huang H
Leuk Res; 2011 Oct; 35(10):1307-11. PubMed ID: 21354617
[TBL] [Abstract][Full Text] [Related]
3. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G
Leuk Res; 2010 Feb; 34(2):143-7. PubMed ID: 19481800
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
Khoury HJ; Kukreja M; Goldman JM; Wang T; Halter J; Arora M; Gupta V; Rizzieri DA; George B; Keating A; Gale RP; Marks DI; McCarthy PL; Woolfrey A; Szer J; Giralt SA; Maziarz RT; Cortes J; Horowitz MM; Lee SJ
Bone Marrow Transplant; 2012 Jun; 47(6):810-6. PubMed ID: 21986636
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Kantarjian HM; O'Brien S; Cortes JE; Giralt SA; Rios MB; Shan J; Giles FJ; Thomas DA; Faderl S; De Lima M; Garcia-Manero G; Champlin R; Arlinghaus R; Talpaz M
Blood; 2002 Sep; 100(5):1590-5. PubMed ID: 12176876
[TBL] [Abstract][Full Text] [Related]
6. Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.
McCann SR; Gately K; Conneally E; Lawler M
Blood; 2003 Feb; 101(3):1200-1. PubMed ID: 12529295
[No Abstract] [Full Text] [Related]
7. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia.
Bhatt VR; Akhtari M; Bociek RG; Sanmann JN; Yuan J; Dave BJ; Sanger WG; Kessinger A; Armitage JO
J Natl Compr Canc Netw; 2014 Jul; 12(7):963-8. PubMed ID: 24994916
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
[TBL] [Abstract][Full Text] [Related]
9. Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration.
Sohn SK; Kim JG; Kim DH; Lee KB
Br J Haematol; 2003 May; 121(3):469-72. PubMed ID: 12716370
[TBL] [Abstract][Full Text] [Related]
10. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
11. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
12. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.
Jain N; van Besien K
Hematol Oncol Clin North Am; 2011 Oct; 25(5):1025-48, vi. PubMed ID: 22054733
[TBL] [Abstract][Full Text] [Related]
13. [Treatment efficacy of imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in chronic phase].
Gao GL; Xu N; Zhou X; Xiao YJ; Ding L; Lu QS; Wei YQ; Zhang Y; Xu D; Sun J; Liu QF; Liu XL
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3035-9. PubMed ID: 24417923
[TBL] [Abstract][Full Text] [Related]
14. Implications of imatinib mesylate for hematopoietic stem cell transplantation.
Goldman J
Semin Hematol; 2001 Jul; 38(3 Suppl 8):28-34. PubMed ID: 11526599
[TBL] [Abstract][Full Text] [Related]
15. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
16. Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.
Ullmann AJ; Hess G; Kolbe K; Friedrich-Freksa A; Meyer RG; Gschaidmeier H; Huber C; Fischer T
Keio J Med; 2003 Sep; 52(3):182-8. PubMed ID: 14529151
[TBL] [Abstract][Full Text] [Related]
17. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Deau B; Nicolini FE; Guilhot J; Huguet F; Guerci A; Legros L; Pautas C; Berthou C; Guyotat D; Cony-Makhoul P; Gardembas M; Michallet M; Hayette S; Cayuela JM; Weiss IR; Réa D; Castaigne S; Mahon FX; Guilhot F; Rousselot P
Leuk Res; 2011 Jun; 35(6):777-82. PubMed ID: 21145590
[TBL] [Abstract][Full Text] [Related]
18. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
Simon W; Segel GB; Lichtman MA
Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.
Goldman J
Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S11-S13. PubMed ID: 18724281
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
Weisser M; Schleuning M; Haferlach C; Schwerdtfeger R; Kolb HJ
Leuk Lymphoma; 2007 Feb; 48(2):295-301. PubMed ID: 17325889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
